| Autor: |
Akgül, Sebahat Usta, Temurhan, Sonay, Çınar, Çiğdem Kekik, Çiftçi, Hayriye Şentürk, Bayraktar, Adem, Demir, Erol, Uçar, Ali Rıza, Bakkaloğlu, Hüseyin, Türkmen, Aydın, Oğuz, Fatma Savran |
| Předmět: |
|
| Zdroj: |
Turkish Journal of Nephrology; Jan2024, Vol. 33 Issue 1, p102-109, 8p |
| Abstrakt: |
Objective: Anti-thymocyte globulin-Fresenius is used for induction treatment in kidney transplantation. The antibody of rabbit originated against human leukocyte antigen A3 were demonstrated in the serum of patients who used anti-thymocyte globulin-Fresenius. We investigated whether anti-human leukocyte antigen A3 antibodies detected due to anti-thymocyte globulin administration had any effect on patient and allograft survival in short- and long-term follow-up. Methods: Fifty-one patients who underwent kidney transplantation between 2004 and 2014 were included in the study. Twenty-nine patients who underwent transplantation from deceased donors received an induction therapy consisting of anti-thymocyte globulin-Fresenius. Antibodies against the human leukocyte antigen were identified using the LABScreen panel reactive antibody class I/II kits with the Luminex method. The graft function and loss, patient survival, and the presence of acute/chronic rejection were investigated. Results: Anti-human leukocyte antigen A3 antibody was detected in 41.3% of the patients receiving anti-thymocyte globulin induction (P = .001). This antibody disappeared at 234.4 days posttransplant. No difference was found regarding pretrans-plant and posttransplant sensitization of the patients who had posttransplant anti-human leukocyte antigen A3 positivity. The anti-thymocyte globulin dose and administration period were similar for anti-human leukocyte antigen A3 antibody-positive and -negative patients (P >.05). There was no significant difference between groups in short-term, first year, and long-term results of serum creatinine, estimated glomerular filtration rate, and proteinuria values (P >.05). Conclusion: We demonstrated that xenogeneic anti-human leukocyte antigen A3 antibody could be detected in posttransplant serum of patients receiving anti-thymocyte globulin induction independent of the dose and duration. The development of this antibody was independent of the exposure of the patient to pre- and posttransplant sensitizing event or the presence of human leukocyte antigen A3 in the allograft. While this study did not demonstrate the effect of xenogeneic anti-human leukocyte antigen A3 antibody on graft and patient survival, retrospective multicenter cohort studies are needed on this issue. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
